Information Provided By:
Fly News Breaks for March 3, 2020
FATE
Mar 3, 2020 | 07:35 EDT
BTIG analyst Amanda Murphy raised the firm's price target on Fate Therapeutics to $42 from $27 and keeps a Buy rating on the shares after its Q4 earnings call and given the "broad applicability" of its iPSC platform. The analyst notes that the stock is up 58% year-to-date, but she continues to see it as undervalued given its potential to have 6 iPSC-derived product candidates in the clinic in 2020. Murphy is also raising her estimated value for Fate's platform to $2B from $740M prior forecast.
News For FATE From the Last 2 Days
There are no results for your query FATE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.